Samjin Pharmaceutical Co. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Samjin Pharmaceutical Co. Ltd.
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.
Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.
Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.
The South Korean biopharma sector is adopting new approaches to beef up original R&D including open innovation, with Hanmi and LegoChem both recently setting up new operations to pursue collaborations as they look to expand internationally.
- OTC, Consumer
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.